Pablo Pergola is a Nephrology physician affiliated with Renal Associates P. A.. OpenAlex indexes 229 publications with 11,590 citations (h-index 55); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1123 N Main Ave Ste 120
San Antonio, TX 782124738
Telephone
210-226-2001Registry record last updated 21 Jan 2019.
Clinical trials
- P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
Sponsor: ZyVersa Therapeutics, Inc.
- Safety Study of GCS-100 to Treat Chronic Kidney Disease
Sponsor: La Jolla Pharmaceutical Company
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20256 payments
- CSL BehringProgram year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year202520 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
52.7%Angiotensin receptor blocker (ARB)9.6%Candesartan Cilexetil55%Losartan Potassium31%Valsartan15%Part D<11 patientsBeta blocker7.1%Carvedilol31%Bisoprolol Fumarate30%Metoprolol Succinate24%Metoprolol Tartrate15%Part D<11 patients+ 11 more classes in this area
Metabolism & gastrointestinal
35.2%SGLT2 inhibitor21.5%Jardiance64%Farxiga32%Invokana4%Part D<11 patientsGLP-1 receptor agonist8.6%Trulicity58%Ozempic42%Part D≥16 patients+ 5 more classes in this area
Musculoskeletal
6%Xanthine oxidase inhibitor6%Allopurinol100%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
The Lancet Diabetes & Endocrinology
2023 - Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
The Lancet Diabetes & Endocrinology
2023 - Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
Nephrology Dialysis Transplantation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”